4,706 Shares in Apogee Therapeutics Inc. $APGE Purchased by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. acquired a new stake in shares of Apogee Therapeutics Inc. (NASDAQ:APGE) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 4,706 shares of the company’s stock, valued at approximately $625,000.

Several other large investors also recently modified their holdings of APGE. GAMMA Investing LLC boosted its position in Apogee Therapeutics by 40.5% in the second quarter. GAMMA Investing LLC now owns 309 shares of the company’s stock valued at $41,000 after buying an additional 89 shares in the last quarter. Rockefeller Capital Management L.P. acquired a new stake in shares of Apogee Therapeutics during the fourth quarter worth approximately $25,000. Los Angeles Capital Management LLC acquired a new stake in shares of Apogee Therapeutics during the fourth quarter worth approximately $37,000. Longfellow Investment Management Co. LLC bought a new position in shares of Apogee Therapeutics in the second quarter valued at approximately $81,000. Finally, EverSource Wealth Advisors LLC raised its stake in shares of Apogee Therapeutics by 61.7% in the first quarter. EverSource Wealth Advisors LLC now owns 645 shares of the company’s stock valued at $54,000 after acquiring an additional 246 shares during the last quarter. 79.04% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Rothschild & Co Redburn began coverage on Apogee Therapeutics in a report on Friday, May 1st. They issued a “buy” rating and a $140.00 target price on the stock. Wedbush downgraded Apogee Therapeutics from an “outperform” rating to a “neutral” rating and set a $135.00 price objective for the company. in a research report on Monday, June 22nd. Craig Hallum set a $135.11 price objective on Apogee Therapeutics and gave the company a “hold” rating in a research report on Monday, June 22nd. Citigroup lowered Apogee Therapeutics from a “buy” rating to a “neutral” rating and boosted their price objective for the stock from $125.00 to $135.00 in a research note on Tuesday, June 23rd. Finally, UBS Group cut Apogee Therapeutics from a “buy” rating to a “neutral” rating and increased their target price for the stock from $100.00 to $135.11 in a report on Tuesday, June 23rd. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, fifteen have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $124.43.

Apogee Therapeutics Price Performance

Shares of NASDAQ:APGE opened at $134.71 on Thursday. The company has a market capitalization of $8.38 billion, a price-to-earnings ratio of -31.04 and a beta of 0.34. The firm’s 50 day simple moving average is $127.48 and its 200 day simple moving average is $95.34. Apogee Therapeutics Inc. has a fifty-two week low of $35.39 and a fifty-two week high of $134.88.

Apogee Therapeutics (NASDAQ:APGE) last issued its earnings results on Monday, August 10th. The company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($1.07) by ($0.07). Equities research analysts expect that Apogee Therapeutics Inc. will post -4.47 earnings per share for the current year.

Insider Buying and Selling at Apogee Therapeutics

In related news, insider Carl Dambkowski sold 26,400 shares of the firm’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $132.60, for a total transaction of $3,500,640.00. Following the sale, the insider owned 179,248 shares of the company’s stock, valued at approximately $23,768,284.80. This trade represents a 12.84% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Michael Thomas Henderson sold 80,000 shares of Apogee Therapeutics stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $132.54, for a total value of $10,603,200.00. Following the transaction, the chief executive officer owned 1,015,987 shares in the company, valued at approximately $134,658,916.98. This represents a 7.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 162,900 shares of company stock valued at $20,344,950 in the last three months. 24.30% of the stock is owned by company insiders.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.